INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 160 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $358,218 | +131.1% | 26,673 | +137.8% | 0.12% | +51.9% |
| Q2 2022 | $155,000 | -52.5% | 11,216 | +173.6% | 0.08% | -64.5% |
| Q2 2019 | $326,000 | -71.8% | 4,099 | -79.3% | 0.22% | -35.8% |
| Q4 2017 | $1,156,000 | +123.6% | 19,786 | +122.3% | 0.34% | +131.5% |
| Q3 2017 | $517,000 | -28.8% | 8,900 | +48.3% | 0.15% | -41.8% |
| Q2 2017 | $726,000 | +64.6% | 6,000 | +53.8% | 0.25% | +39.4% |
| Q1 2017 | $441,000 | – | 3,900 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |